Do analysts rate PHXM or IXHL?

Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 453.85%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, PHXM or IXHL?

PHAXIAM Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Incannex Healthcare $90K 432.25 -$46.88M -$1.55 N/A

Is PHXM or IXHL more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Incannex Healthcare N/A -81.01% -76.11%

Do analysts rate PHXM or ATHE?

Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 121.24%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, PHXM or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is PHXM or ATHE more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Alterity Therapeutics N/A N/A N/A

Do analysts rate CRVO or PHXM?

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 726.77%. Given CervoMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe CervoMed is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CRVO or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 9.58 -$26.97M -$3.22 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Which has better valuation and earnings, PHXM or CPHI?

PHAXIAM Therapeutics has higher earnings, but lower revenue than China Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A China Pharma $3.91M 9.23 -$3.08M -$0.43 N/A

Do analysts rate PHXM or ACTU?

Actuate Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 666.42%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, PHXM or ACTU?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is PHXM or ACTU more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Actuate Therapeutics N/A -346.19% -178.40%

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 09/2/2026

Compare

PHXM vs. IXHL, ATHE, CRVO, CPHI, and ACTU

Should you buy PHAXIAM Therapeutics stock or one of its competitors? PHAXIAM Therapeutics's main competitors and comparable companies include Incannex Healthcare (IXHL), Alterity Therapeutics (ATHE), CervoMed (CRVO), China Pharma (CPHI), and Actuate Therapeutics (ACTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Incannex Healthcare	Neutral

Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 453.85%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PHAXIAM Therapeutics has higher earnings, but lower revenue than Incannex Healthcare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Incannex Healthcare	$90K	432.25	-$46.88M	-$1.55	N/A

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Incannex Healthcare	N/A	-81.01%	-76.11%

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, suggesting that its stock price is 597% more volatile than the broader market.

Summary

Incannex Healthcare beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 121.24%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	N/A

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

In the previous week, Alterity Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Alterity Therapeutics	Neutral

PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

Alterity Therapeutics beats PHAXIAM Therapeutics on 6 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to CervoMed?

CervoMed (NASDAQ:CRVO) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PHAXIAM Therapeutics has lower revenue, but higher earnings than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.58	-$26.97M	-$3.22	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 726.77%. Given CervoMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe CervoMed is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PHAXIAM Therapeutics' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, CervoMed's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
PHAXIAM Therapeutics	Neutral

CervoMed has a beta of -0.64, indicating that its stock price is 164% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Summary

CervoMed beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to China Pharma?

PHAXIAM Therapeutics (NASDAQ:PHXM) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

PHAXIAM Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. PHAXIAM Therapeutics' return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
China Pharma	-85.56%	-63.93%	-31.42%

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
China Pharma	Neutral

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

PHAXIAM Therapeutics has higher earnings, but lower revenue than China Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
China Pharma	$3.91M	9.23	-$3.08M	-$0.43	N/A

Summary

PHAXIAM Therapeutics beats China Pharma on 6 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Actuate Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

PHAXIAM Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Actuate Therapeutics	N/A	-346.19%	-178.40%

PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Actuate Therapeutics' average media sentiment score of 1.00 beat PHAXIAM Therapeutics' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Actuate Therapeutics	Positive

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Actuate Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 666.42%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

Summary

PHAXIAM Therapeutics and Actuate Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.58M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	N/A	787.27	273.29	25.38
Price / Sales	N/A	753.78	613.45	97.56
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.39	12.33	12.89	6.14
Net Income	-$240K	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.59%	0.60%	-0.27%
1 Month Performance	N/A	6.95%	5.73%	0.68%
1 Year Performance	N/A	9.45%	25.35%	14.84%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
IXHL Incannex Healthcare	1.7432 of 5 stars	$3.18 -5.1%	$18.00 +466.0%	-82.6%	$40.08M	$90K	N/A	3
ATHE Alterity Therapeutics	2.2427 of 5 stars	$4.55 +1.3%	$10.00 +119.8%	-10.8%	$39.81M	N/A	N/A	10	News Coverage Gap Up
CRVO CervoMed	2.7873 of 5 stars	$2.57 -2.3%	$21.00 +717.1%	-76.2%	$39.76M	$4.01M	N/A	4
CPHI China Pharma	N/A	$0.89 0.0%	N/A	-42.1%	$38.09M	$3.91M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. IXHL, ATHE, CRVO, CPHI, and ACTU

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to CervoMed?

Summary

How does PHAXIAM Therapeutics compare to China Pharma?

Summary

How does PHAXIAM Therapeutics compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. IXHL, ATHE, CRVO, CPHI, and ACTU

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Does the media prefer PHXM or IXHL?

Do analysts rate PHXM or IXHL?

Which has better earnings & valuation, PHXM or IXHL?

Is PHXM or IXHL more profitable?

Do institutionals and insiders hold more shares of PHXM or IXHL?

Which has more risk and volatility, PHXM or IXHL?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Do analysts rate PHXM or ATHE?

Is PHXM or ATHE more profitable?

Do institutionals & insiders hold more shares of PHXM or ATHE?

Which has stronger earnings & valuation, PHXM or ATHE?

Does the media refer more to PHXM or ATHE?

Which has more risk & volatility, PHXM or ATHE?

Summary

How does PHAXIAM Therapeutics compare to CervoMed?

Do insiders and institutionals believe in CRVO or PHXM?

Which has preferable valuation and earnings, CRVO or PHXM?

Do analysts rate CRVO or PHXM?

Is CRVO or PHXM more profitable?

Does the media favor CRVO or PHXM?

Which has more risk and volatility, CRVO or PHXM?

Summary

How does PHAXIAM Therapeutics compare to China Pharma?

Is PHXM or CPHI more profitable?

Do institutionals & insiders hold more shares of PHXM or CPHI?

Does the media refer more to PHXM or CPHI?

Which has more volatility & risk, PHXM or CPHI?

Which has better valuation and earnings, PHXM or CPHI?

Summary

How does PHAXIAM Therapeutics compare to Actuate Therapeutics?

Is PHXM or ACTU more profitable?

Which has more volatility and risk, PHXM or ACTU?

Does the media favor PHXM or ACTU?

Do institutionals and insiders hold more shares of PHXM or ACTU?

Do analysts rate PHXM or ACTU?

Which has stronger earnings & valuation, PHXM or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools